Illumina, Inc.
Illumina Announces Q2 2024 Financial Results and Lowered FY 2024 Guidance
Summary
Illumina, Inc. announced its financial results for the second quarter of fiscal year 2024, reporting Core Illumina revenue of $1.09 billion, a 6% decrease from Q2 2023. Non-GAAP diluted earnings per share for Q2 2024 were $1.09. The company also lowered its FY 2024 Core Illumina revenue guidance to a decline of 2% to 3% (down 1.5% to 2.5% in constant currency) from 2023, and raised its non-GAAP operating margin guidance to a range of 20.5% to 21%. Illumina introduced guidance for FY 2024 Core Illumina non-GAAP diluted earnings per share in the range of $3.80 to $3.95.
Profitelligence Alerts
Get alerts for ILMN
Be first to know when Illumina, Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Illumina, Inc.
Illumina, Inc. operates as a global leader in the life sciences industry, focusing on the development and manufacturing of integrated systems for the analysis of genetic variation and function. Primarily, Illumina’s products and services are pivotal in advancing genomic research, enabling scientists to explore DNA sequencing and genetic mapping with high precision and efficiency. The company’s solutions are extensively utilized in fields such as oncology, reproductive health, and genetic disease diagnostics. Known for its cutting-edge sequencing tools, Illumina plays a crucial role in driving innovation in personalized medicine, helping to tailor medical treatments to individual genetic profiles. Headquartered in San Diego, California, Illumina contributes significantly to the genomics sector’s expansion, supporting initiatives in health and medicine, agrigenomics, and microbiology. By providing critical tools for genetic analysis, Illumina aids researchers and clinical laboratories worldwide, influencing how healthcare is approached and offering insights into complex biological systems.
Official SEC Documents
Advertisement